SPORE in Prostate Cancer

前列腺癌中的孢子

• 批准号: 8609795
• 负责人: William J Catalona
• 金额: $ 4.8万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-06-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8609795
• 关键词: 5a-Reductase Inhibition; Ablation; Advanced Malignant Neoplasm; Advisory Committees; Advocacy; Androgens; Animals; Bioinformatics; Biostatistics Core; Chemopreventive Agent; Clinical Trials; Development; Disease; Environment; Equilibrium; Genistein; Leadership; Leptin; Local Therapy; Malignant neoplasm of prostate; Molecular Epidemiology; Prevention; Principal Investigator; Prostate Cancer therapy; Published Comment; Radiation; Regulation; Research; Research Personnel; Research Project Grants; Review Committee; Robert H Lurie Comprehensive Cancer Center of Northwestern University; Specimen; Structure; Translational Research; Tumor Necrosis Factor-alpha; University of Chicago Cancer Research Center; anticancer research; career development; cell motility; flexibility; human TNF protein; improved; lipid biosynthesis; patient population; pigment epithelium-derived factor; programs; prostate cancer cell; research and development

This is a revised application for renewal of the SPORE in Prostate Cancer at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Cancer Research Center of the University of Chicago. Overall, the reviewers noted that the Program had considerable merit with strengths in the expertise of the investigators, large patient population and an environment highly supportive of the SPORE. We have responded to the comments made by the review committee through extensive revisions and, thus, have further enhanced the program throughout. The major changes can be found in Project 4 where we now focus on animal studies and a clinical trial and in Project 2 where we have eliminated one aim to conduct animal studies. The revised application contains four highly translational research projects: (1) 5a-Reductase Inhibition in Intermittent Androgen Ablation Therapy of Prostate Cancer (Wang & Shevrin), (2) PEDF Regulation of Adipogenesis and Leptin in Prostate Cancer (Crawford, Gapstur and Lee), (3) Radiation-lnducible TNF-alpha Therapy in Prostate Cancer (Weichselbaum & Stadler) and (4) Modulation of Prostate Cancer Cell Motility by the Chemopreventive Agent Genistein (Bergan & Catalona). These projects represent a balanced approach in prostate cancer translational research, including prevention (Project 4), molecular epidemiology (Project 2), management of androgen-sensitive advanced cancer (Project 1), and therapy of local disease (project 3). The leadership of the SPORE emphasizes the highly interactive structures in place for the proposed four cores, that include the Administrative Core, the Specimen Procurement Core, the Biostatistics/Bioinformatics Core, and the Clinical Trials and Advocacy Core. The SPORE also has flexible, yet structured, Developmental Research and Career Development Programs to encourage additional investigators to undertake initiatives in prostate cancer research and to quickly respond to new research opportunities. The Internal and External Advisory Committees evaluate program progress and offer guidance to the SPORE principal investigator and co-principal investigators. We feel that the revised application is significantly improved, and we are grateful to the reviewers for their helpful comments.

这是西北大学罗伯特·H·卢里综合癌症中心和芝加哥大学癌症研究中心前列腺癌 SPORE 更新的修订申请。总体而言，评审员指出，该计划具有相当大的优点，包括研究人员的专业知识、大量的患者群体以及高度支持 SPORE 的环境。我们针对评审委员会提出的意见进行了广泛的修改，从而进一步完善了整个方案。主要变化可以在项目 4 中找到，我们现在专注于动物研究和临床试验，而在项目 2 中，我们取消了进行动物研究的目标。修订后的申请包含四个高度转化的研究项目：(1) 前列腺癌间歇性雄激素消融治疗中的 5a-还原酶抑制 (Wang 和 Shevrin)，(2) PEDF 对前列腺癌中脂肪生成和瘦素的调节 (Crawford、Gapstur 和 Lee)，(3) 前列腺癌中的放射诱导 TNF-α 治疗 (Weichselbaum) & Stadler）和（4）化学预防剂金雀异黄素对前列腺癌细胞运动的调节（Bergan & Catalona）。这些项目代表了前列腺癌转化研究的平衡方法，包括预防（项目 4）、分子流行病学（项目 2）、雄激素敏感晚期癌症的管理（项目 1）和局部疾病的治疗（项目 3）。 SPORE 的领导层强调了拟议的四个核心的高度互动结构，包括行政核心、标本采购核心、生物统计/生物信息学核心以及临床试验和宣传核心。 SPORE 还拥有灵活但结构化的发展研究和职业发展计划，以鼓励更多研究人员采取主动性前列腺癌研究并快速响应新的研究机会。内部和外部咨询委员会评估项目进展并为 SPORE 首席研究员和联合首席研究员提供指导。我们认为修改后的应用程序有了显着的改进，我们感谢审稿人的有益评论。

项目成果

U19/Eaf2 binds to and stabilizes von hippel-lindau protein.

• DOI: 10.1158/0008-5472.can-08-2595
• 发表时间: 2009-03-15
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Xiao W;Ai J;Habermacher G;Volpert O;Yang X;Zhang AY;Hahn J;Cai X;Wang Z
• 通讯作者: Wang Z

Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor.

恶性前列腺细胞中转化生长因子β1 的过度表达部分是由TGF-β1 自诱导失控引起的，该失控是通过TGF-β I 型受体招募蛋白磷酸酶2A 的缺陷介导的。

• DOI: 10.1016/j.urology.2010.03.061
• 发表时间: 2010
• 期刊: Urology
• 影响因子: 2.1
• 作者: Yu,Nengwang;Kozlowski,JamesM;Park,IrwinI;Chen,Lin;Zhang,Qiang;Xu,Danfeng;Doll,JenniferA;Crawford,SusanE;Brendler,CharlesB;Lee,Chung
• 通讯作者: Lee,Chung

Natural products and transforming growth factor-beta (TGF-β) signaling in cancer development and progression.

癌症发生和进展中的天然产物和转化生长因子-β (TGF-β) 信号传导。

• DOI: 10.2174/15680096113139990034
• 发表时间: 2013
• 期刊: Current cancer drug targets
• 影响因子: 3
• 作者: Lee,Chung;Zhang,Qiang;Kozlowski,James;Brendler,Charles;BSoares,Marcelo;Dash,Atrya;McClelland,Michael;Mercola,Dan
• 通讯作者: Mercola,Dan

What Is the True Number Needed to Screen and Treat to Save a Life With Prostate-Specific Antigen Testing?

• DOI: 10.1200/jco.2010.30.6373
• 发表时间: 2011-02-01
• 期刊: JOURNAL OF CLINICAL ONCOLOGY
• 影响因子: 45.3
• 作者: Loeb, Stacy;Vonesh, Edward F.;Catalona, William J.
• 通讯作者: Catalona, William J.

Investigation of discrete imaging models and iterative image reconstruction in differential X-ray phase-contrast tomography.

• DOI: 10.1364/oe.20.010724
• 发表时间: 2012-05-07
• 期刊: Optics express
• 影响因子: 3.8
• 作者: Xu Q;Sidky EY;Pan X;Stampanoni M;Modregger P;Anastasio MA
• 通讯作者: Anastasio MA